<DOC>
	<DOCNO>NCT02014558</DOCNO>
	<brief_summary>The objective study assess safety tolerability , include maximum tolerated dose , ASP2215 subject relapse treatment-refractory acute myeloid leukemia ( AML ) . This study also determine pharmacokinetic ( PK ) parameter ASP2215 .</brief_summary>
	<brief_title>Dose Escalation Study Investigating Safety , Tolerability , Pharmacokinetics , Pharmacodynamics ASP2215 Patients With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Subject define morphologically document primary secondary AML World Health Organization ( WHO ) criterion ( 2008 ) fulfill one following : Refractory least 1 cycle induction chemotherapy Relapsed achieve remission prior therapy Subject Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . Subject 's interval prior treatment time study drug administration least 2 week cytotoxic agent ( except hydroxyurea give control blast cell ) , least 5 halflives prior experimental agent noncytotoxic agent . Subject must meet follow criterion indicate clinical laboratory tests* : Serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2.5 x institutional upper limit normal ( ULN ) Total serum bilirubin &lt; 1.5x institutional ULN Serum creatinine &lt; 1.5 x institutional ULN estimate glomerular filtration rate ( eGFR ) &gt; 50 ml/min calculate Modification Diet Renal Disease ( MDRD ) equation . Subject agree participate another interventional study treatment . Subject diagnose acute promyelocytic leukemia ( APL ) . Subject BCRABLpositive leukemia ( chronic myelogenous leukemia blast crisis ) . Subject active malignant tumor AML Myelodysplastic syndrome ( MDS ) . Subject persistent nonhematological toxicity &gt; = Grade 2 ( Common Terminology Criteria Adverse Events v4 ) , symptom objective finding , prior AML treatment ( include chemotherapy , kinase inhibitor , immunotherapy , experimental agent , radiation , surgery ) . Subject hematopoietic stem cell transplant ( HSCT ) meet follow : Is within 2 month transplant C1D1 Has clinically significant graftversushost disease require treatment Has &gt; = Grade 2 persistent nonhematological toxicity relate transplant . Donor lymphocytes infusion ( DLI ) permit &lt; = 30 day prior study registration first cycle treatment study Cohort 1 first two cycle treatment Cohort 2 Subject clinically active central nervous system leukemia Subject disseminate intravascular coagulation abnormality ( DIC ) Subject major surgery within 4 week prior first study dose . Subject radiation therapy within 4 week prior first study dose Subject congestive heart failure New York Heart Association ( NYHA ) class 3 4 , subject history congestive heart failure NYHA class 3 4 past , unless screen echocardiogram perform within 3 month prior study entry result leave ventricular ejection fraction ≥ 45 % Subject require treatment concomitant drug strong inhibitor inducer Cytochrome P450isozyme3A4 ( CYP3A4 ) exception antibiotic , antifungal , antiviral use standard care posttransplant prevent treat infection drug consider absolutely essential care subject Subject require treatment concomitant drug target serotonin 5HT1R 5HT2BR receptor sigma nonspecific receptor exception drug consider absolutely essential care subject . Subject active uncontrolled infection Subject know human immunodeficiency virus infection Subject active hepatitis B C , active hepatic disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>ASP2215</keyword>
</DOC>